Read-Gene S.A. (WSE:RDG)

Read-Gene Statistics

Total Valuation

Read-Gene has a market cap or net worth of PLN 70.74 million. The enterprise value is 70.15 million.

Market Cap	70.74M
Enterprise Value	70.15M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Read-Gene has 11.79 million shares outstanding.

Current Share Class	1.49M
Shares Outstanding	11.79M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.16%
Owned by Institutions (%)	n/a
Float	1.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.68
PB Ratio	24.25
P/TBV Ratio	24.25
P/FCF Ratio	14.88
P/OCF Ratio	13.84
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 97.35, with an EV/FCF ratio of 14.76.

EV / Earnings	-173.43
EV / Sales	4.64
EV / EBITDA	97.35
EV / EBIT	249.58
EV / FCF	14.76

Financial Position

The company has a current ratio of 2.85, with a Debt / Equity ratio of 2.71.

Current Ratio	2.85
Quick Ratio	2.85
Debt / Equity	2.71
Debt / EBITDA	10.97
Debt / FCF	1.66
Interest Coverage	0.85

Financial Efficiency

Return on equity (ROE) is -12.89% and return on invested capital (ROIC) is 1.62%.

Return on Equity (ROE)	-12.89%
Return on Assets (ROA)	1.14%
Return on Invested Capital (ROIC)	1.62%
Return on Capital Employed (ROCE)	2.19%
Revenue Per Employee	687,672
Profits Per Employee	-18,386
Employee Count	30
Asset Turnover	0.98
Inventory Turnover	201.00

Taxes

In the past 12 months, Read-Gene has paid 489,916 in taxes.

Income Tax	489,916
Effective Tax Rate	573.54%

Stock Price Statistics

The stock price has increased by +19.52% in the last 52 weeks. The beta is 0.74, so Read-Gene's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	+19.52%
50-Day Moving Average	6.09
200-Day Moving Average	5.03
Relative Strength Index (RSI)	45.10
Average Volume (20 Days)	534

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Read-Gene had revenue of PLN 15.13 million and -404,497 in losses.

Revenue	15.13M
Gross Profit	14.19M
Operating Income	281,077
Pretax Income	85,419
Net Income	-404,497
EBITDA	720,642
EBIT	281,077
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 8.50 million in cash and 7.91 million in debt, giving a net cash position of 589,064 or 0.05 per share.

Cash & Cash Equivalents	8.50M
Total Debt	7.91M
Net Cash	589,064
Net Cash Per Share	0.05
Equity (Book Value)	2.92M
Book Value Per Share	n/a
Working Capital	7.13M

Cash Flow

In the last 12 months, operating cash flow was 5.11 million and capital expenditures -357,983, giving a free cash flow of 4.75 million.

Operating Cash Flow	5.11M
Capital Expenditures	-357,983
Free Cash Flow	4.75M
FCF Per Share	0.40

Margins

Gross margin is 93.82%, with operating and profit margins of 1.86% and -2.67%.

Gross Margin	93.82%
Operating Margin	1.86%
Pretax Margin	0.56%
Profit Margin	-2.67%
EBITDA Margin	4.76%
EBIT Margin	1.86%
FCF Margin	31.41%

Dividends & Yields

Read-Gene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-0.57%
FCF Yield	6.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Read-Gene has an Altman Z-Score of 3.74 and a Piotroski F-Score of 5.

Altman Z-Score	3.74
Piotroski F-Score	5